DUBLIN, Ireland, Oct. 10, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third-quarter 2017 financial results will be released on Monday, Nov. 6, 2017. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and a replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 96805714. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 96805714.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:
Investors:
Tina Ventura
Senior Vice President,
Investor Relations
[email protected]
Ruth Venning
Executive Director,
Investor Relations
[email protected]
U.S. Media:
Geoff Curtis
Senior Vice President,
Corporate Affairs & Chief Communications Officer
[email protected]
Ireland Media:
Ray Gordon
Gordon MRM
[email protected]


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



